Jeffery DR - Search Results

1

Fingolimod: a review of its mode of action in the context of its efficacy and safety profile in relapsing forms of multiple sclerosis.

Jeffery DR, Rammohan KW, Hawker K, Fox E. Jeffery DR, et al. Expert Rev Neurother. 2016;16(1):31-44. doi: 10.1586/14737175.2016.1123094. Epub 2016 Jan 13. Expert Rev Neurother. 2016. PMID: 26587577 Review.

2

Use of adrenocorticosteroid hormones in the treatment of multiple sclerosis.

Jeffery DR. Jeffery DR. Expert Rev Neurother. 2002 Nov;2(6):859-66. doi: 10.1586/14737175.2.6.859. Expert Rev Neurother. 2002. PMID: 19810919

3

Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis.

Radue EW, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Rudick RA, Lublin FD, Weinstock-Guttman B, Wynn DR, Fisher E, Papadopoulou A, Lynn F, Panzara MA, Sandrock AW; SENTINEL Investigators. Radue EW, et al. J Neurol Sci. 2010 May 15;292(1-2):28-35. doi: 10.1016/j.jns.2010.02.012. Epub 2010 Mar 16. J Neurol Sci. 2010. PMID: 20236661 Clinical Trial.

4

A phase 3 trial of extended release oral dalfampridine in multiple sclerosis.

Goodman AD, Brown TR, Edwards KR, Krupp LB, Schapiro RT, Cohen R, Marinucci LN, Blight AR; MSF204 Investigators. Goodman AD, et al. Ann Neurol. 2010 Oct;68(4):494-502. doi: 10.1002/ana.22240. Ann Neurol. 2010. PMID: 20976768 Clinical Trial.

5

Fingolimod for the treatment of relapsing multiple sclerosis.

Jeffery DR, Markowitz CE, Reder AT, Weinstock-Guttman B, Tobias K. Jeffery DR, et al. Expert Rev Neurother. 2011 Feb;11(2):165-83. doi: 10.1586/ern.10.193. Epub 2010 Dec 16. Expert Rev Neurother. 2011. PMID: 21158700 Review.

6

Efficacy of natalizumab therapy in patients of African descent with relapsing multiple sclerosis: analysis of AFFIRM and SENTINEL data.

Cree BA, Stuart WH, Tornatore CS, Jeffery DR, Pace AL, Cha CH. Cree BA, et al. Among authors: jeffery dr. Arch Neurol. 2011 Apr;68(4):464-8. doi: 10.1001/archneurol.2011.45. Arch Neurol. 2011. PMID: 21482925 Clinical Trial.

7

The relationship between the rate of brain volume loss during first 24 months and disability progression over 24 and 48 months in relapsing MS.

Jeffery DR, Di Cantogno EV, Ritter S, Meier DP, Radue EW, Camu W. Jeffery DR, et al. J Neurol. 2016 Feb;263(2):299-305. doi: 10.1007/s00415-015-7959-1. Epub 2015 Nov 14. J Neurol. 2016. PMID: 26568562 Clinical Trial.

8

Early intervention with immunomodulatory agents in the treatment of multiple sclerosis.

Jeffery DR. Jeffery DR. J Neurol Sci. 2002 May 15;197(1-2):1-8. doi: 10.1016/s0022-510x(02)00039-4. J Neurol Sci. 2002. PMID: 11997060 Review.

9

Review of mitoxantrone in the treatment of multiple sclerosis.

Jeffery DR, Herndon R. Jeffery DR, et al. Neurology. 2004 Dec 28;63(12 Suppl 6):S19-24. doi: 10.1212/wnl.63.12_suppl_6.s19. Neurology. 2004. PMID: 15623665 Review.

10

Effects of inhibitors of the renin-angiotensin system on the efficacy of interferon beta-1b: a post hoc analysis of the BEYOND study.

Doerner M, Beckmann K, Knappertz V, Kappos L, Hartung HP, Filippi M, O'Connor PW, Arnason B, Cook S, Jeffery D, Comi G, Limmroth V. Doerner M, et al. Eur Neurol. 2014;71(3-4):173-9. doi: 10.1159/000355530. Epub 2014 Jan 21. Eur Neurol. 2014. PMID: 24457374 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

54 results

Search Page

Filters